查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
C型肝炎治療的全球市場:成長，未來預測，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1180644

C型肝炎治療的全球市場:成長，未來預測，競爭分析(2022年～2030年)

Hepatitis C Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

C型肝炎的盛行率增加，診斷技術的提高，治療藥的取得容易度，開發平台分子的強大存在感，推動全球C型肝炎治療市場成長。

本報告提供全球C型肝炎治療市場相關調查分析，市場趨勢，競爭分析，市場動態，各市場區隔、各地區的市場分析，企業簡介等系統性資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 C型肝炎治療市場:競爭分析

  • 主要的C型肝炎治療市場供應商的市場定位
  • C型肝炎治療市場供應商採用的策略
  • 主要的產業策略
  • 階層分析:2021年對2030年

第4章 C型肝炎治療市場:常量分析和市場動態

  • 簡介
  • 全球C型肝炎治療的市場價值(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要機會
  • 促進因素與阻礙因素的影響分析
  • See-Saw分析

第5章 C型肝炎治療市場:各藥物(2020年～2030年)

  • 市場概要
  • 成長、收益分析:2021年對2030年
  • 市場明細
    • 干擾素
    • Ribavirin
    • 直接作用型抗病毒藥物(DAA)

第6章 北美的C型肝炎治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 北美

第7章 英國、EU的C型肝炎治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 英國、EU

第8章 亞太地區的C型肝炎治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 亞太地區

第9章 南美的C型肝炎治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 南美

第10章 中東、非洲的C型肝炎治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 中東、非洲

第11章 企業簡介

  • AbbieVie Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmith Kline Plc.
  • Janssen Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Schering AG
  • Vertex Pharmaceuticals
Product Code: 137654-08-22

A hepatitis C is inflammatory disease of the liver caused by infection with hepatitis C virus (HCV). Increasing prevalence hepatitis C, improved diagnostic techniques, easy availability of treatment medication and strong presence of pipeline molecules are driving the growth of hepatitis C treatment market globally.

The report titled "Hepatitis C treatment Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall hepatitis C treatment market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug type and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hepatitis C treatment market. In depth analysis of pipeline molecule for key products hepatitis C treatment, global epidemiology data for hepatitis C have been included in report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global hepatitis C treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global hepatitis C treatment market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hepatitis C Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Hepatitis C Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

Interferons

Peginterferon alfa-2a

Peginterferon alfa-2b

Interferon alfa-2b

Ribavirin

Direct-Acting Antivirals (DAA)

Protease Inhibitor (Paritaprevir, Simepravir, Grazoprevir)

Polymerase Inhibitors

Other Drugs

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Hepatitis C Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Hepatitis C Treatment market?

Which is the largest regional market for Hepatitis C Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Hepatitis C Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Hepatitis C Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Hepatitis C Treatment Market
  • 2.2. Global Hepatitis C Treatment Market, By Drug, 2021 (US$ Million)
  • 2.3. Global Hepatitis C Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Hepatitis C Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Hepatitis C Treatment Market Vendors
  • 3.2. Strategies Adopted by Hepatitis C Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Hepatitis C Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Hepatitis C Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Interferons
      • 5.3.1.1. Peginterferon alfa-2a
      • 5.3.1.2. Peginterferon alfa-2b
      • 5.3.1.3. Interferon alfa-2b
    • 5.3.2. Ribavirin
    • 5.3.3. Direct-Acting Antivirals (DAA)
      • 5.3.3.1. Protease Inhibitor (Paritaprevir, Simepravir, Grazoprevir)
      • 5.3.3.2. Polymerase Inhibitors
      • 5.3.3.3. Other Drugs

6. North America Hepatitis C Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
  • 6.3.Hepatitis C Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)

7. UK and European Union Hepatitis C Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
  • 7.3.Hepatitis C Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)

8. Asia Pacific Hepatitis C Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
  • 8.3.Hepatitis C Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)

9. Latin America Hepatitis C Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
  • 9.3.Hepatitis C Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)

10. Middle East and Africa Hepatitis C Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
  • 10.3.Hepatitis C Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Hepatitis C Treatment Market: By Drug, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. AbbieVie Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Bristol-Myers Squibb Company
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. F. Hoffmann-La Roche AG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Gilead Sciences Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. GlaxoSmith Kline Plc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Janssen Pharmaceuticals Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Merck & Co. Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Schering AG
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Vertex Pharmaceuticals
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 2 Global Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 3 Global Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 4 North America Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 5 North America Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 6 North America Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 7 U.S. Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 8 U.S. Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 9 U.S. Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 10 Canada Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 11 Canada Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 12 Canada Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 13 Rest of North America Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 14 Rest of North America Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 15 Rest of North America Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 16 UK and European Union Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 17 UK and European Union Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 18 UK and European Union Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 19 UK Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 20 UK Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 21 UK Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 22 Germany Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 23 Germany Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 24 Germany Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 25 Spain Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 26 Spain Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 27 Spain Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 28 Italy Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 29 Italy Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 30 Italy Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 31 France Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 32 France Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 33 France Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 34 Rest of Europe Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 35 Rest of Europe Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 36 Rest of Europe Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 37 Asia Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 38 Asia Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 39 Asia Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 40 China Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 41 China Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 42 China Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 43 Japan Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 44 Japan Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 45 Japan Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 46 India Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 47 India Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 48 India Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 49 Australia Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 50 Australia Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 51 Australia Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 52 South Korea Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 53 South Korea Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 54 South Korea Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 55 Latin America Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 56 Latin America Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 57 Latin America Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 58 Brazil Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 59 Brazil Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 60 Brazil Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 61 Mexico Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 62 Mexico Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 63 Mexico Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 64 Rest of Latin America Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 65 Rest of Latin America Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 66 Rest of Latin America Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 67 Middle East and Africa Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 68 Middle East and Africa Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 69 Middle East and Africa Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 70 GCC Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 71 GCC Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 72 GCC Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 73 Africa Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 74 Africa Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 75 Africa Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)
  • TABLE 76 Rest of Middle East and Africa Hepatitis C Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 77 Rest of Middle East and Africa Hepatitis C Treatment Market By Interferons, 2020-2030, USD (Million)
  • TABLE 78 Rest of Middle East and Africa Hepatitis C Treatment Market By Direct-Acting Antivirals (DAA), 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Hepatitis C Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Hepatitis C Treatment Market: Quality Assurance
  • FIG. 5 Global Hepatitis C Treatment Market, By Drug, 2021
  • FIG. 6 Global Hepatitis C Treatment Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Hepatitis C Treatment Market, 2021
  • FIG. 8 Market Positioning of Key Hepatitis C Treatment Market Players, 2021
  • FIG. 9 Global Hepatitis C Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Hepatitis C Treatment Market, By Drug, 2021 Vs 2030, %
  • FIG. 11 U.S. Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 France Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 China Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 India Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Hepatitis C Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Hepatitis C Treatment Market (US$ Million), 2020 - 2030